X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (571) 571
Patent (173) 173
Publication (33) 33
Conference Proceeding (5) 5
Book Chapter (3) 3
Reference (2) 2
Book Review (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (288) 288
peptides (178) 178
chemistry (173) 173
metallurgy (173) 173
organic chemistry (172) 172
microbiology (157) 157
biochemistry (156) 156
beer (155) 155
enzymology (155) 155
male (155) 155
mutation or genetic engineering (155) 155
spirits (155) 155
vinegar (155) 155
wine (155) 155
female (152) 152
index medicus (151) 151
middle aged (148) 148
oncology (142) 142
compositions thereof (138) 138
culture media (138) 138
microorganisms or enzymes (138) 138
propagating, preserving or maintaining microorganisms (138) 138
human necessities (128) 128
hygiene (128) 128
medical or veterinary science (128) 128
preparations for medical, dental, or toilet purposes (128) 128
physics (122) 122
adult (119) 119
investigating or analysing materials by determining theirchemical or physical properties (119) 119
measuring (119) 119
testing (119) 119
aged (117) 117
compositions or test papers therefor (114) 114
condition-responsive control in microbiological orenzymological processes (114) 114
measuring or testing processes involving enzymes, nucleicacids or microorganisms (114) 114
processes of preparing such compositions (114) 114
hematology (97) 97
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (69) 69
treatment outcome (63) 63
adolescent (61) 61
rituximab (61) 61
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
prognosis (49) 49
specific therapeutic activity of chemical compounds ormedicinal preparations (49) 49
cancer (48) 48
chemotherapy (47) 47
non-hodgkins-lymphoma (47) 47
lymphomas (44) 44
aged, 80 and over (43) 43
antigens, neoplasm - immunology (42) 42
young adult (42) 42
elderly-patients (41) 41
cyclophosphamide - administration & dosage (40) 40
nucleic acids (40) 40
sugars (40) 40
derivatives thereof (39) 39
nucleosides (39) 39
nucleotides (39) 39
doxorubicin - administration & dosage (38) 38
immunology (37) 37
vincristine - administration & dosage (37) 37
antineoplastic combined chemotherapy protocols - administration & dosage (36) 36
abridged index medicus (34) 34
animals (33) 33
disease-free survival (33) 33
expression (33) 33
prednisone - administration & dosage (33) 33
risk factors (33) 33
therapy (32) 32
general tagging of cross-sectional technologies spanning over several sections of the ipc (31) 31
general tagging of new technological developments (31) 31
technical subjects covered by former uspc (31) 31
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (31) 31
immunotherapy (30) 30
lymphoma (30) 30
lymphoma, large b-cell, diffuse - drug therapy (30) 30
survival (30) 30
identification (29) 29
cyclophosphamide (28) 28
analysis (27) 27
mice (27) 27
transplantation (26) 26
b-cell lymphoma (25) 25
antibodies, monoclonal - therapeutic use (24) 24
antigens, neoplasm - genetics (24) 24
survival analysis (24) 24
disease (23) 23
care and treatment (22) 22
molecular sequence data (22) 22
trial (22) 22
cytolytic t-lymphocytes (21) 21
doxorubicin (21) 21
lymphocytes (21) 21
randomized controlled-trial (21) 21
survival rate (21) 21
time factors (21) 21
3-weekly chop chemotherapy (20) 20
chemotherapy plus rituximab (20) 20
patients (20) 20
stem cells (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (725) 725
French (74) 74
German (60) 60
Chinese (2) 2
Danish (2) 2
Korean (2) 2
Portuguese (2) 2
Spanish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 05/2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2008, Volume 52, Issue 6, pp. 470 - 482
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 2, pp. 105 - 116
Journal Article
Journal Article
by Trotman, Judith and Barrington, Sally F and Belada, David and Meignan, Michel and MacEwan, Robert and Owen, Carolyn and Ptáčník, Václav and Rosta, András and Fingerle-Rowson, Günter R and Zhu, Jiawen and Zhu, Jun and Nielsen, Tina and Sahin, Deniz and Hiddemann, Wolfgang and Marcus, Robert E and Davies, Andrew and Hertzberg, Mark and Grigg, Andrew and Cannell, Paul and Quach, Hang and Opat, Stephen and Tam, Constantine and Marlton, Paula and Janssens, Ann and Offner, Fritz and Van eygen, Koen and Sangha, Randeep and Mckay, Pam and Wilson, Jonathan and Van Der Jagt, Richard and Roitman, Daryl and Trneny, Marek and Mayer, Jiri and Le Du, Katell and Solal-Celigny, Philippe and Cartron, Guillaume and Foussard, Charles and Frickhofen, Norbert and Schmidt, Peter and Graeven, Ullrich and Gaska, Tobias and Schlag, Rudolf and Sökler, Martin and Prange-Krex, Gabriele and Florschütz, Axel and Lindemann, Hans-Walter and Schimmelpfennig, Christoph and Tonndorf, Solveig and Hänel, Mathias and Hess, Georg and Schalk, Enrico and Hütten, Heiko and Doelken, Gottfried and Pfreundschuh, Michael and Keller, Ulrich and Herold, Michael and Forstpointner, Roswitha and Vehling-Kaiser, Ursula and Hoffmann, Martin and Borbenyi, Zita and Udvardy, Miklos and Demeter, Judit and Rambaldi, Alessandro and Morra, Enrica and Massimo, Federico and Majolino, Ignazio and Balzarotti, Monica and Semenzato, Gianpietro and Canales Albendea, Miguel Angel and Peñalver Parraga, Francisco Javier and Soler Campos, Alfonso and Sancho Cia, Juan Manuel and Marquez Navarro, Jose Antonio and Grande Garcia, Carlos and Nilsson-Ehle, Herman and Mccarthy, Helen and Pocock, Chris and Sadullah, Shalal and Malladi, Ram and Radford, John and Kanfer, Ed and Kruger, Anton and Culligan, Dominic and Dyer, Martin and Pettengell, Ruth and Seymour, John and Gribben, John and Al-Ismail, Saad and Al-Refaie, Faris and Blesing, Norbert and Macnamara, Christopher and O'callaghan, Ann and Haynes, Andrew and Follows, George and Johnson, Roderick and Cunningham, David and Bowles, Kristian and Collins, Graham and Gallop-Evans, Eve and Robinson, Stephen and ... and PET investigators GALLIUM study and PET investigators from the GALLIUM study
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1530 - 1542
Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line... 
FDG-PET | CRITERIA | FONDAZIONE ITALIANA LINFOMI | SUBSET ANALYSIS | POSITRON-EMISSION-TOMOGRAPHY | INTERNATIONAL WORKSHOP | THERAPY | ONCOLOGY | PROGRESSION-FREE SURVIVAL | FOLL05 TRIAL | MINIMAL RESIDUAL DISEASE | Pets | Lymphomas | Prognosis | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2009, Volume 27, Issue 4, pp. 511 - 518
Purpose Mantle cell lymphomas (MCLs) represent a clinically aggressive lymphoma subtype with a poor prognosis. To explore a potential progress in outcome a... 
UNITED-STATES | EUROPEAN-MCL-NETWORK | PROSPECTIVE RANDOMIZED-TRIAL | ONCOLOGY | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | VINCRISTINE | NON-HODGKINS-LYMPHOMA | CHEMOTHERAPY | TRANSPLANTATION | Lymphoma, Mantle-Cell - mortality | Lymphoma, Mantle-Cell - therapy | Humans | Middle Aged | Aged, 80 and over | Adult | Female | Male | Survival Rate | Aged
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1013 - 1022
Journal Article